Gyre Therapeutics (NASDAQ:GYRE) Shares Gap Down – Time to Sell?

Gyre Therapeutics, Inc. (NASDAQ:GYRE) shares gapped down before the market opened on Thursday . The stock had previously closed at $8.33, but opened at $7.84. Gyre Therapeutics shares last traded at $7.86, with a volume of 114,918 shares changing hands.

Analyst Ratings Changes

A number of equities analysts have commented on GYRE shares. Weiss Ratings restated a “sell (d)” rating on shares of Gyre Therapeutics in a research note on Thursday, January 22nd. Wall Street Zen raised shares of Gyre Therapeutics from a “hold” rating to a “buy” rating in a research note on Saturday, November 15th. Finally, Zacks Research upgraded Gyre Therapeutics from a “strong sell” rating to a “hold” rating in a report on Friday, November 14th. Two research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has given a Sell rating to the company. According to MarketBeat.com, the stock presently has an average rating of “Hold” and an average price target of $17.00.

Gyre Therapeutics Stock Down 3.8%

The firm has a 50 day moving average price of $7.93 and a 200 day moving average price of $7.79. The stock has a market cap of $772.08 million, a PE ratio of 267.22 and a beta of 1.97.

Gyre Therapeutics (NASDAQ:GYRE) last released its quarterly earnings data on Monday, March 16th. The company reported ($0.02) earnings per share for the quarter, missing analysts’ consensus estimates of $0.08 by ($0.10). Gyre Therapeutics had a return on equity of 9.50% and a net margin of 6.20%.The business had revenue of $37.20 million during the quarter, compared to analysts’ expectations of $36.30 million.

Hedge Funds Weigh In On Gyre Therapeutics

A number of hedge funds and other institutional investors have recently modified their holdings of the business. Geode Capital Management LLC increased its holdings in Gyre Therapeutics by 13.0% during the fourth quarter. Geode Capital Management LLC now owns 423,222 shares of the company’s stock valued at $2,989,000 after buying an additional 48,602 shares during the period. SBI Securities Co. Ltd. lifted its holdings in Gyre Therapeutics by 87.9% during the second quarter. SBI Securities Co. Ltd. now owns 232,299 shares of the company’s stock worth $1,707,000 after buying an additional 108,670 shares during the period. State Street Corp boosted its position in Gyre Therapeutics by 10.7% during the 4th quarter. State Street Corp now owns 202,225 shares of the company’s stock valued at $1,428,000 after acquiring an additional 19,472 shares in the last quarter. Charles Schwab Investment Management Inc. boosted its position in Gyre Therapeutics by 37.1% during the 4th quarter. Charles Schwab Investment Management Inc. now owns 169,158 shares of the company’s stock valued at $1,194,000 after acquiring an additional 45,772 shares in the last quarter. Finally, Millennium Management LLC purchased a new position in shares of Gyre Therapeutics in the 3rd quarter valued at $267,000. 23.99% of the stock is currently owned by institutional investors.

About Gyre Therapeutics

Gyre Therapeutics, Inc is a clinical-stage biotechnology company focused on discovering and developing small-molecule therapies that target lipid biology to treat a range of metabolic, inflammatory and neurodegenerative diseases. The company’s proprietary platform combines lipidomic profiling with drug discovery tools to identify compounds that selectively modulate membrane lipid composition and restore normal protein function in disease-relevant cells.

Gyre’s preclinical pipeline includes programs in nonalcoholic steatohepatitis (NASH), Alzheimer’s disease and autoimmune conditions, reflecting its strategy of applying a unified lipid-targeted approach across multiple therapeutic areas.